The Clinical Research Committee (CRC) at the Lombardi Comprehensive Cancer Center (Lombardi) is responsible for reviewing clinical research protocols for scientific merit, ensuring prioritization of protocols based on scientific priorities and patient availability, and monitoring the scientific progress of cancer protocols. As part of the initial scientific review, the CRC also identifies protocols that need institutional data and safety monitoring oversight if a data and safety monitoring plan is already in place for the trial, Lombardi resources are not used for this purpose. For example, NCI/CTEP-sponsored phase I and II studies are reported by the principal investigator (PI) to the NCI/CTEP, and all clinical trials sponsored by the NCI Cooperative Group Program (CALGB, NSABP, ECOG, SWOG, and COG) comply with cooperative group data submission, reporting, review, and monitoring procedures. The CRC Co-Chairs specifically identify studies for which no formal data and safety monitoring plan exists, and the Pis of those studies report to and have their studies monitored and audited by the DSMC. The Lombardi Data and Safety Monitoring Plan was submitted to the NCI and approved on June 13, 2002. A copy of this plan will be available at the site visit The Data and Safety Monitoring Committee (DSMC) consists of clinical researchers, with representation from physicians, biostatisticians, pharmacists, and data managers. The DSMC meets quarterly to evaluate all investigator-initiated phase I and II studies, PI investigational new drug (IND)-holder phase I and II studies, and NCI-supported trials without any monitoring mechanism in place. Pis of studies requiring data and safety monitoring are required to submit a data and safety report every 3 months from the date of Institutional Review Board (IRB) approval. These reports address any changes made to the protocol, a summary of adverse events experienced by subjects on the study and include any serious adverse event report submitted by the PI. The report is reviewed at the quarterly DSMC meeting. All adverse events are reviewed quarterly for each study requiring DSMC review. This approach is designed to identify protocols that may place a patient at excessive risk for toxicity so that studies may be terminated or suspended accordingly. An internal review of each study is conducted every 3 months that consists of three medical charts and case report forms (or 10%, whichever is higher). Reports of these reviews are reviewed at the quarterly DSMC meeting. The DSMC provides a prospective analysis of data acquisition and safety at Lombardi in order to maintain excellent research data and patient safety. Specifically, the DSMC provide 'real-time' and frequent review of institutional phase I and II studies, as well as of NCI-sponsored studies that do not have an external monitoring plan.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
United States
Zip Code
Paffhausen, Emily S; Alowais, Yasir; Chao, Cara W et al. (2018) Discovery of a stem-like multipotent cell fate. Am J Stem Cells 7:25-37
Lee, Shiao-Pieng; Kao, Chen-Yu; Chang, Shun-Cheng et al. (2018) Tissue distribution and subcellular localizations determine in vivo functional relationship among prostasin, matriptase, HAI-1, and HAI-2 in human skin. PLoS One 13:e0192632
Tiek, D M; Rone, J D; Graham, G T et al. (2018) Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma. Sci Rep 8:7222
Akinyemiju, Tomi F; Demb, Joshua; Izano, Monika A et al. (2018) The association of early life socioeconomic position on breast cancer incidence and mortality: a systematic review. Int J Public Health 63:787-797
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Furth, Priscilla A (2018) Peroxisome proliferator-activated receptor gamma and BRCA1. Endocr Relat Cancer :
Oppong, Bridget A; Dash, Chiranjeev; O'Neill, Suzanne et al. (2018) Breast density in multiethnic women presenting for screening mammography. Breast J 24:334-338
Gusev, Yuriy; Bhuvaneshwar, Krithika; Song, Lei et al. (2018) The REMBRANDT study, a large collection of genomic data from brain cancer patients. Sci Data 5:180158
Schmidt, Marcel Oliver; Garman, Khalid Ammar; Lee, Yong Gu et al. (2018) The Role of Fibroblast Growth Factor-Binding Protein 1 in Skin Carcinogenesis and Inflammation. J Invest Dermatol 138:179-188
Fernandez, Harvey R; Gadre, Shreyas M; Tan, Mingjun et al. (2018) The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ 25:1239-1258

Showing the most recent 10 out of 1120 publications